A new look at the neonatal bowel-contrast studies with metrizamide (Amipaque).
Metrizamide is the first water-soluble radiographic contrast agent which, because it is nonionic, can be used in isotonic solution and gives good visualization of the desired body structure. Its only major disadvantage is that it is very expensive. Metrizamide can be used to study the neonatal bowel in clinical situations where all the other existing contrast agents are contraindicated. The results of 55 metrizamide studies of the bowel in infants are reviewed. In necrotizing enterocolitis metrizamide aids in confirming or rejecting the diagnosis, identifying patients for surgery, and in evaluating the response to surgery. Metrizamide can identify the etiology in unusual cases of bowel obstruction. Metrizamide correctly identified a thoracic origin of free peritoneal air in four cases and a bowel origin in two cases. It identified bowel perforation in two patients in the absence of pneumoperitoneum. In six patients, the metrizamide study identified the cause for a gasless abdomen. It is concluded that metrizamide has a valuable role to play in evaluating a variety of neonatal bowel disorders.
D004341:Drug Evaluation; D004761:Enterocolitis, Pseudomembranous / Q000000981:diagnostic imaging; D006801:Humans; D007231:Infant, Newborn; D007415:Intestinal Obstruction / Q000000981:diagnostic imaging; D007416:Intestinal Perforation / Q000000981:diagnostic imaging; D007422:Intestines / Q000000981:diagnostic imaging*; D008793:Metrizamide; D011859:Radiography
D008793:Metrizamide